Study
Longitudinal association of dietary spermidine with hepatic function indexes and cardiometabolic traits in older adults with metabolic syndrome.
Higher dietary spermidine intake over one year tracked with better liver and cardiometabolic markers in 2,664 adults, without proving cause.
Summary Does eating more spermidine improve liver and heart-health markers? Show / hide ↓
Researchers followed 2,664 older adults who were overweight or obese and had metabolic syndrome, a group of conditions that raise the risk of diabetes and heart disease. They estimated spermidine intake using a food questionnaire and compared changes in people’s diets with changes in health measurements over one year. People whose intake was highest and increased further had a fatty-liver score that was about 9 points lower on average. This was an observational study, meaning the researchers observed eating habits rather than assigning people a treatment, so other lifestyle differences could explain the result.
What this means for you: This does not show that spermidine caused better health, and it did not test a spermidine supplement or longer life. There is not enough evidence to buy a supplement based on this study; focus instead on a generally healthy eating pattern.
weak evidenceThis longitudinal analysis used baseline and one-year data from 2,664 PREDIMED-Plus participants who were older, overweight or obese, and had metabolic syndrome. It assessed dietary spermidine intake with a semi-quantitative food-frequency questionnaire rather than assigning a spermidine supplement. The investigators grouped people into three patterns of intake change across baseline, six months and one year, then used linear mixed-effects models to examine associations with hepatic and cardiometabolic markers. The pattern with the highest baseline intake and a further increase over one year was associated with a mean fatty-liver-index reduction of 8.97 points (95% CI -9.96 to -7.97). The supplied abstract truncates immediately after this result, so it does not provide the other effect estimates or p-values. Its conclusion says that increased dietary spermidine intake was associated with improved hepatic-function indices and cardiometabolic traits. Association is the operative word. Dietary reporting, clustering and observational modelling cannot establish that spermidine itself caused the changes. This is not a randomised supplement trial and does not test a longevity outcome. It concerns a metabolic-syndrome population over one year, so its relevance to healthy people is limited.
A one-year increase in dietary spermidine intake was associated with improvements in hepatic-function indices and cardiometabolic traits in older adults with metabolic syndrome.
This was an observational dietary analysis, not a randomised spermidine-supplement trial, so confounding remains likely. Intake came from a food-frequency questionnaire, and the supplied results are truncated after one fatty-liver-index estimate.
Cited by
1 encyclopedia entries reference this study.